Sfoglia per Autore
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression
2019-01-01 Daga, Martina; Pizzimenti, Stefania*; Dianzani, Chiara; Cucci, Marie Angele; Cavalli, Roberta; Grattarola, Margherita; Ferrara, Benedetta; Scariot, Valentina; Trotta, Francesco; Barrera, Giuseppina
Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells
2019-01-01 Cucci M.A.; Compagnone A.; Daga M.; Grattarola M.; Ullio C.; Roetto A.; Palmieri A.; Rosa A.C.; Argenziano M.; Cavalli R.; Simile M.M.; Pascale R.M.; Dianzani C.; Barrera G.; Pizzimenti S.
Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism
2020-01-01 Cucci M.A.; Grattarola M.; Dianzani C.; Damia G.; Ricci F.; Roetto A.; Trotta F.; Barrera G.; Pizzimenti S.
Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells
2020-01-01 Ambrosio L.; Argenziano M.; Cucci M.A.; Grattarola M.; de Graaf I.A.M.; Dianzani C.; Barrera G.; Nieves J.S.; Gomez R.; Cavalli R.; Pizzimenti S.
Nrf2, YAP, antioxidant potential, and cancer
2021-01-01 Giuseppina Barrera, Marie Angele Cucci, Margherita Grattarola, Stefania Pizzimenti
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role
2021-01-01 Barrera G.; Cucci M.A.; Grattarola M.; Dianzani C.; Muzio G.; Pizzimenti S.
Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies
2021-01-01 Pizzimenti S.; Ribero S.; Cucci M.A.; Grattarola M.; Monge C.; Dianzani C.; Barrera G.; Muzio G.
Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells
2021-01-01 Grattarola M.; Cucci M.A.; Roetto A.; Dianzani C.; Barrera G.; Pizzimenti S.
MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
2022-01-01 Sequera, Celia; Grattarola, Margherita; Holczbauer, Agnes; Dono, Rosanna; Pizzimenti, Stefania; Barrera, Giuseppina; Wangensteen, Kirk J; Maina, Flavio
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma
2022-01-01 Argenziano M.; Bessone F.; Dianzani C.; Cucci M.A.; Grattarola M.; Pizzimenti S.; Cavalli R.
Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma
2023-01-01 Foglietta, Federica; Bozza, Annalisa; Ferraris, Chiara; Cangemi, Luigi; Bordano, Valentina; Serpe, Loredana; Martina, Katia; Lazzarato, Loretta; Pizzimenti, Stefania; Grattarola, Margherita; Cucci, Marie Angele; Dianzani, Chiara; Battaglia, Luigi
Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications
2023-01-01 Boggio E.; Gigliotti C.L.; Stoppa I.; Pantham D.; Sacchetti S.; Rolla R.; Grattarola M.; Monge C.; Pizzimenti S.; Dianzani U.; Dianzani C.; Battaglia L.
Nrf2 role in the BRAFi/MEKi acquired resistance in melanoma
2023-01-01 M.A.Cucci, M. Grattarola, C. Monge, A. Roetto, C. Dianzani, S.Pizzimenti
Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle
2023-01-01 Azzimonti B.; Ballacchino C.; Zanetta P.; Cucci M.A.; Monge C.; Grattarola M.; Dianzani C.; Barrera G.; Pizzimenti S.
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
2023-01-01 Cucci M.A.; Grattarola M.; Monge C.; Roetto A.; Barrera G.; Caputo E.; Dianzani C.; Pizzimenti S.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression | 2019 | Daga, Martina; Pizzimenti, Stefania*; Dianzani, Chiara; Cucci, Marie Angele; Cavalli, Roberta; Grattarola, Margherita; Ferrara, Benedetta; Scariot, Valentina; Trotta, Francesco; Barrera, Giuseppina | |
| Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells | 2019 | Cucci M.A.; Compagnone A.; Daga M.; Grattarola M.; Ullio C.; Roetto A.; Palmieri A.; Rosa A.C.; Argenziano M.; Cavalli R.; Simile M.M.; Pascale R.M.; Dianzani C.; Barrera G.; Pizzimenti S. | |
| Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism | 2020 | Cucci M.A.; Grattarola M.; Dianzani C.; Damia G.; Ricci F.; Roetto A.; Trotta F.; Barrera G.; Pizzimenti S. | |
| Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells | 2020 | Ambrosio L.; Argenziano M.; Cucci M.A.; Grattarola M.; de Graaf I.A.M.; Dianzani C.; Barrera G.; Nieves J.S.; Gomez R.; Cavalli R.; Pizzimenti S. | |
| Nrf2, YAP, antioxidant potential, and cancer | 2021 | Giuseppina Barrera, Marie Angele Cucci, Margherita Grattarola, Stefania Pizzimenti | |
| Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role | 2021 | Barrera G.; Cucci M.A.; Grattarola M.; Dianzani C.; Muzio G.; Pizzimenti S. | |
| Oxidative stress-related mechanisms in melanoma and in the acquired resistance to targeted therapies | 2021 | Pizzimenti S.; Ribero S.; Cucci M.A.; Grattarola M.; Monge C.; Dianzani C.; Barrera G.; Muzio G. | |
| Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells | 2021 | Grattarola M.; Cucci M.A.; Roetto A.; Dianzani C.; Barrera G.; Pizzimenti S. | |
| MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities | 2022 | Sequera, Celia; Grattarola, Margherita; Holczbauer, Agnes; Dono, Rosanna; Pizzimenti, Stefania; Barrera, Giuseppina; Wangensteen, Kirk J; Maina, Flavio | |
| Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma | 2022 | Argenziano M.; Bessone F.; Dianzani C.; Cucci M.A.; Grattarola M.; Pizzimenti S.; Cavalli R. | |
| Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma | 2023 | Foglietta, Federica; Bozza, Annalisa; Ferraris, Chiara; Cangemi, Luigi; Bordano, Valentina; Serpe, Loredana; Martina, Katia; Lazzarato, Loretta; Pizzimenti, Stefania; Grattarola, Margherita; Cucci, Marie Angele; Dianzani, Chiara; Battaglia, Luigi | |
| Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications | 2023 | Boggio E.; Gigliotti C.L.; Stoppa I.; Pantham D.; Sacchetti S.; Rolla R.; Grattarola M.; Monge C.; Pizzimenti S.; Dianzani U.; Dianzani C.; Battaglia L. | |
| Nrf2 role in the BRAFi/MEKi acquired resistance in melanoma | 2023 | M.A.Cucci, M. Grattarola, C. Monge, A. Roetto, C. Dianzani, S.Pizzimenti | |
| Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle | 2023 | Azzimonti B.; Ballacchino C.; Zanetta P.; Cucci M.A.; Monge C.; Grattarola M.; Dianzani C.; Barrera G.; Pizzimenti S. | |
| Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma | 2023 | Cucci M.A.; Grattarola M.; Monge C.; Roetto A.; Barrera G.; Caputo E.; Dianzani C.; Pizzimenti S. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile